For example, in a randomized study of lestaurtinib administered in sequence with intensive chemotherapy for FLT3-mutated AML, the addition of lestaurtinib did not lead to an improved outcome (Levis et al., 2011). This evidence concerns the gene FLT3 and acute myeloid leukemia.